---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-053645"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:44:13.621857+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nkarta gets FDA IND clearance for NKX019 in LN; cuts workforce 10%, extends cash runway

## Summary
- FDA cleared IND for NKX019 (CAR NK) for lupus nephritis; enrollment starts H1 2024; up to 12 patients.
- RIF of 18 employees (~10% workforce); $1M-$1.5M severance costs in Q4 2023; extends cash runway into 2026.
- Preliminary cash $278.4M as of Sep 30, 2023; cash runway extended one year into 2026.
- NKX019 NHL: new compressed dosing cohort (Days 0,3,7) for LBCL; prior expansion cohorts discontinued.
- Clinical updates in 2024: NKX101 AML H1, NKX019 NHL mid-2024, NKX019 LN in 2024.

## SEC filing metadata
- accession: 0000950170-23-053645
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/0000950170-23-053645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/nktx-20231016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-053645
- JSON: https://secwatch.observer/filing/0000950170-23-053645.json
- Plain text: https://secwatch.observer/filing/0000950170-23-053645.txt

## Key facts
- Restructurings & Charges
  Nkarta, Inc. announced a restructuring with charges of approximately $1 million to $1.5 million affecting Reduction in force of 18 positions, representing approximately 10% of the Company's workforce (reduction of 18 positions).
  - Type: restructuring
  - Charge: approximately $1 million to $1.5 million
  - Affected area: Reduction in force of 18 positions, representing approximately 10% of the Company's workforce
  - Headcount: reduction of 18 positions
  source text: to extend the Company’s cash runway by one year into 2026. In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $1 million to $1.5 million in costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/0000950170-23-053645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.